These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30084044)

  • 21. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
    Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
    Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applications of nanoparticles for diagnosis and therapy of cancer.
    Baetke SC; Lammers T; Kiessling F
    Br J Radiol; 2015 Oct; 88(1054):20150207. PubMed ID: 25969868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery.
    Dhaliwal A; Zheng G
    Theranostics; 2019; 9(26):8091-8108. PubMed ID: 31754383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanotheranostics and image-guided drug delivery: current concepts and future directions.
    Lammers T; Kiessling F; Hennink WE; Storm G
    Mol Pharm; 2010 Dec; 7(6):1899-912. PubMed ID: 20822168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Development of Drug Delivery Technology and Nanomedicine by Using Gold Nanoparticles].
    Ozeki T; Tagami T
    Yakugaku Zasshi; 2021; 141(3):323-326. PubMed ID: 33642498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theranostic systems and strategies for monitoring nanomedicine-mediated drug targeting.
    Kunjachan S; Jayapaul J; Mertens ME; Storm G; Kiessling F; Lammers T
    Curr Pharm Biotechnol; 2012 Mar; 13(4):609-22. PubMed ID: 22214503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission tomography image-guided drug delivery: current status and future perspectives.
    Chakravarty R; Hong H; Cai W
    Mol Pharm; 2014 Nov; 11(11):3777-97. PubMed ID: 24865108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
    Natfji AA; Ravishankar D; Osborn HMI; Greco F
    J Pharm Sci; 2017 Nov; 106(11):3179-3187. PubMed ID: 28669714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery.
    Liu X; Jiang J; Meng H
    Theranostics; 2019; 9(26):8018-8025. PubMed ID: 31754378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
    Swetha KL; Roy A
    Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting endothelial permeability in the EPR effect.
    Lahooti B; Akwii RG; Zahra FT; Sajib MS; Lamprou M; Alobaida A; Lionakis MS; Mattheolabakis G; Mikelis CM
    J Control Release; 2023 Sep; 361():212-235. PubMed ID: 37517543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation.
    Ikeda-Imafuku M; Wang LL; Rodrigues D; Shaha S; Zhao Z; Mitragotri S
    J Control Release; 2022 May; 345():512-536. PubMed ID: 35337939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle.
    Miller MA; Gadde S; Pfirschke C; Engblom C; Sprachman MM; Kohler RH; Yang KS; Laughney AM; Wojtkiewicz G; Kamaly N; Bhonagiri S; Pittet MJ; Farokhzad OC; Weissleder R
    Sci Transl Med; 2015 Nov; 7(314):314ra183. PubMed ID: 26582898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomedicine(s) under the microscope.
    Duncan R; Gaspar R
    Mol Pharm; 2011 Dec; 8(6):2101-41. PubMed ID: 21974749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
    Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
    Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanomedicine and drug delivery systems in cancer and regenerative medicine.
    Garbayo E; Pascual-Gil S; Rodríguez-Nogales C; Saludas L; Estella-Hermoso de Mendoza A; Blanco-Prieto MJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1637. PubMed ID: 32351045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Companion Diagnostic
    Lee H; Gaddy D; Ventura M; Bernards N; de Souza R; Kirpotin D; Wickham T; Fitzgerald J; Zheng J; Hendriks BS
    Theranostics; 2018; 8(9):2300-2312. PubMed ID: 29721081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms.
    Zi Y; Yang K; He J; Wu Z; Liu J; Zhang W
    Adv Drug Deliv Rev; 2022 Sep; 188():114449. PubMed ID: 35835353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.